New Antimicrobials (new + antimicrobial)

Distribution by Scientific Domains

Terms modified by New Antimicrobials

  • new antimicrobial agent

  • Selected Abstracts


    Methicillin-resistant Staphylococcus aureus and beyond: what's new in the world of the ,golden staph'?

    ANZ JOURNAL OF SURGERY, Issue 6 2004
    Caroline Marshall
    Methicillin-resistant Staphylococcus aureus (MRSA) continues to plague our hospitals. With the appearance of isolates that are resistant to vancomycin, now, more than ever, we must direct our efforts to controlling its development and spread. New antimicrobials have become available for treatment, but may only be a short-term answer. Our efforts towards control must be directed towards infection control measures such as improved hand hygiene with user-friendly products, such as alcohol-based hand disinfectants. Intranasal mupirocin may have a place in prevention of surgical site infection, although this role has not yet been clearly defined. Other areas where MRSA control may be effected include prudent controlled use of antibiotics, including surgical prophylaxis. [source]


    Inhibition of pneumococcal choline-binding proteins and cell growth by esters of bicyclic amines

    FEBS JOURNAL, Issue 2 2007
    Beatriz Maestro
    Streptococcus pneumoniae is one of the major pathogens worldwide. The use of currently available antibiotics to treat pneumococcal diseases is hampered by increasing resistance levels; also, capsular polysaccharide-based vaccination is of limited efficacy. Therefore, it is desirable to find targets for the development of new antimicrobial drugs specifically designed to fight pneumococcal infections. Choline-binding proteins are a family of polypeptides, found in all S. pneumoniae strains, that take part in important physiologic processes of this bacterium. Among them are several murein hydrolases whose enzymatic activity is usually inhibited by an excess of choline. Using a simple chromatographic procedure, we have identified several choline analogs able to strongly interact with the choline-binding module (C-LytA) of the major autolysin of S. pneumoniae. Two of these compounds (atropine and ipratropium) display a higher binding affinity to C-LytA than choline, and also increase the stability of the protein. CD and fluorescence spectroscopy analyses revealed that the conformational changes of C-LytA upon binding of these alkaloids are different to those induced by choline, suggesting a different mode of binding. In vitro inhibition assays of three pneumococcal, choline-dependent cell wall lytic enzymes also demonstrated a greater inhibitory efficiency of those molecules. Moreover, atropine and ipratropium strongly inhibited in vitro pneumococcal growth, altering cell morphology and reducing cell viability, a very different response than that observed upon addition of an excess of choline. These results may open up the possibility of the development of bicyclic amines as new antimicrobials for use against pneumococcal pathologies. [source]


    The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?

    FEMS MICROBIOLOGY REVIEWS, Issue 6 2006
    Miguel Vicente
    Abstract While newly developed technologies have revolutionized the classical approaches to combating infectious diseases, the difficulties associated with developing novel antimicrobials mean that these technologies have not yet been used to introduce new compounds into the market. The new technologies, including genomics and structural biology, open up exciting possibilities for the discovery of antibiotics. However, a substantial effort to pursue research, and moreover to incorporate the results into the production chain, is required in order to bring new antimicrobials to the final user. In the current scenario of emerging diseases and the rapid spread of antibiotic resistance, an active policy to support these requirements is vital. Otherwise, many valuable programmes may never be fully developed for lack of "interest" and funds (private and public). Will we react in time to avoid potential disaster? [source]


    Prevention of respiratory infections in the elderly

    GERIATRICS & GERONTOLOGY INTERNATIONAL, Issue 3 2002
    Mutsuo Yamaya
    The risk of nosocomial infections is 3,5-fold higher among older patients than among younger adults. Both the increased incidence of respiratory infections and the high mortality among older people are a consequence of a number of age-related factors, including coexisting illnesses, therapeutic interventions, and the aging process itself. Risk factors for the development of respiratory infections in older people can be broadly classified into factors that alter host defenses and factors that increase exposure to bacteria. These factors combine to adversely affect the person's capacity to defend against pathogens of the upper and lower respiratory tract. Despite the availability of potent new antimicrobials, the increasingly limited treatment efficacy of these antimicrobials is related to emerging microbial resistance. Recently, new methods of treating respiratory infections according to the mechanisms of infection have been introduced. Effective methods of preventing respiratory infections in older people were reviewed. [source]


    Effect of Veillonella parvula on the antimicrobial resistance and gene expression of Streptococcus mutans grown in a dual-species biofilm

    MOLECULAR ORAL MICROBIOLOGY, Issue 3 2008
    S. B. I. Luppens
    Introduction:, Our previous studies showed that Streptococcus mutans and Veillonella parvula dual-species biofilms have a different acid production profile and a higher resistance to chlorhexidine than their single-species counterparts. The aim of the current study was to test whether the susceptibility of S. mutans grown in the presence of V. parvula is also decreased when it is exposed to various other antimicrobials. Furthermore, the aim was to identify other changes in the physiology of S. mutans when V. parvula was present using transcriptomics. Methods:, Susceptibility to antimicrobials was assessed in killing experiments. Transcript levels in S. mutans were measured with the help of S. mutans microarrays. Results:, When V. parvula was present, S. mutans showed an increase in survival after exposure to various antimicrobials. Furthermore, this co-existence altered the physiology of S. mutans. The expression of genes coding for proteins involved in amino acid synthesis, the signal recognition particle-translocation pathway, purine metabolism, intracellular polysaccharide synthesis, and protein synthesis all changed. Conclusion:, Growing in a biofilm together with a non-pathogenic bacterium like V. parvula changes the physiology of S. mutans, and gives this bacterium an advantage in surviving antimicrobial treatment. Thus, the study of pathogens implicated in polymicrobial diseases, such as caries and periodontitis, should be focused more on multispecies biofilms. In addition, the testing of susceptibility to currently used and new antimicrobials should be performed on a multispecies microbial community rather than with single pathogens. [source]


    All EU hands to the EU pumps: the Science Academies of Europe (EASAC) recommend strong support of research to tackle antibacterial resistance

    CLINICAL MICROBIOLOGY AND INFECTION, Issue 10 2008
    2Article first published online: 15 SEP 200, I. C. Gyssens
    Abstract Despite many European Union (EU) conferences on fighting microbial resistance, rates of resistance in Europe continue to increase. Although research is catching up with discovery, the development of new antimicrobials is threatened by economic factors, in particular the need for a return of investment via high-volume sales. The EU should invest in independent research into the economic and business aspects of antibiotic development. Multidisciplinary input from the fields of finance, law, marketing, sociology and psychology will inform a broad agenda for change at the regulatory, academic and commercial levels and identify new options for novel anti-infective research and development, as recently recommended by the Science Academies of Europe (EASAC). [source]